XENE Xenon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XENE

Price (delayed)

$53.05

Market cap

$5.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.7

Enterprise value

$4.59B

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 80
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of ...

Highlights
The company's equity has surged by 130% QoQ and by 90% YoY
The quick ratio has soared by 109% from the previous quarter and by 58% YoY
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Xenon Pharmaceuticals's gross profit has plunged by 100% from the previous quarter and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xenon-pharma.com
Peers: PTCT ATNM

Key stats

What are the main financial stats of XENE

XENE stock price

How has the Xenon Pharmaceuticals stock price performed over time
Intraday
-0.77%
1 week
-3.18%
1 month
-7.58%
1 year
74.16%
YTD
18.36%
QTD
-8.77%

Financial performance

How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$412.66M
Net income
-$383.17M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% QoQ and by 100% YoY
Xenon Pharmaceuticals's gross profit has plunged by 100% from the previous quarter and by 100% YoY
The net income has dropped by 52% year-on-year and by 11% since the previous quarter
The operating income is down by 41% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does XENE's price correlate with its fundamentals

Growth

What is Xenon Pharmaceuticals's growth rate over time

Valuation

What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 46% YoY and by 8% QoQ
The company's equity has surged by 130% QoQ and by 90% YoY
XENE's price to book (P/B) is 29% lower than its last 4 quarters average of 4.7 and 5% lower than its 5-year quarterly average of 3.5
The company's revenue has shrunk by 100% QoQ and by 100% YoY

Efficiency

How efficient is Xenon Pharmaceuticals business performance
XENE's return on invested capital has dropped by 84% year-on-year
Xenon Pharmaceuticals's return on equity has shrunk by 52% YoY but it has increased by 12% QoQ
Xenon Pharmaceuticals's return on assets has shrunk by 51% YoY but it has increased by 11% QoQ

Dividends

What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XENE.

Financial health

How did Xenon Pharmaceuticals financials performed over time
The total assets has soared by 119% since the previous quarter and by 87% year-on-year
The quick ratio has soared by 109% from the previous quarter and by 58% YoY
XENE's debt is 99% smaller than its equity
The company's equity has surged by 130% QoQ and by 90% YoY
XENE's debt is down by 14% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.